Verastem(US:VSTM) ZACKS·2026-02-05 17:45Core Insights - Verastem's shares increased nearly 8% following the announcement of preliminary sales figures for Q4 and FY2025 [1][6] - The company reported expected net product revenues of approximately $17.5 million for Q4 2025 and $30.9 million for the full year 2025, attributed to the U.S. launch of Avmapki Fakzynja Co-pack after FDA approval in May 2025 [2][6] - Verastem ended 2025 with around $205 million in cash and investments, projecting a cash runway into the first half of 2027 [3][6] Financial Performance - Preliminary net product revenues for Q4 2025 are expected to be approximately $17.5 million, while full-year revenues are projected at $30.9 million [2][6] - The company raised $29.4 million through the exercise of outstanding cash warrants by January 25, 2026 [2] Market Position and Growth - Verastem anticipates that the LGSOC commercial launch and development program will become self-sustaining by the second half of 2026, driven by strong sales growth [3][6] - Over the past year, Verastem's shares have increased by 11.4%, compared to a 32.7% rise in the industry [3] Pipeline Developments - The company is focusing on maximizing value from the Avmapki Fakzynja Co-pack launch while advancing a pipeline targeting RAS/MAPK pathway-driven cancers [7] - Avmapki Fakzynja Co-pack is currently being evaluated in the phase III RAMP 301 study, with top-line data expected in mid-2027 [7] - In Japan, the combination drug is being assessed in the mid-stage RAMP201J study, showing a 38% overall response rate, including 57% in KRAS-mutated patients [8] Future Plans - Verastem plans to select the recommended phase II dose in combination with Erbitux (cetuximab) and initiate expansion studies in colorectal cancer in the first half of 2026 [10] - The company aims to report interim data from the phase I/II study of VS-7375 in the first half of 2026 [9] - Updated data on the RAMP 205 study, evaluating avutometinib plus defactinib, is expected in the second quarter of 2026 [11]